SPE Capital looks to acquire up to 40% stake in Future Pharma

M&A WATCH- SPE Capital looks to acquire up to 40% stake in FuturePharma: Emerging markets-focused private equity outfit SPE Capital (Swicorp) is currently in talks to acquire a 30-40%stake in FuturePharma, sources close to the talks tell Al Mal. The transaction is expected to cost SPE up to EGP 400 mn, the source noted. They expected the transaction to close before the end of 1Q2019. SPE has a history of investing in Egypt’s healthcare sector, including OrchidiaPharma, a stake in which it sold to the Egyptian American Enterprise Fund (EAEF) back in 2017.